Skip to main content
    V

    Viridian Therapeutics Inc (VRDN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $29.80
    -1.07 (-3.47%)

    Market Cap: $3.51B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Viridian Therapeutics Inc (VRDN) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Viridian Therapeutics (VRDN) trades at 128.5x sales and 5.8x book value. Its P/S of 128.5x is above its 10-year median of 27.3x. Its forward P/E is 1.0x.

    Current Multiples

    MultipleValue
    P/E (trailing)N/A
    Forward P/E1.0x
    Price to sales128.5x
    Price to book5.8x
    PEGN/A
    FCF yield-10.2%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/B is 152.2% above 2.3x.

    MultipleCurrent5-year median10-year median
    P/S128.5xN/A27.3x
    P/B5.8x2.3x2.3x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 96 to 117 months (10-year).

    Valuation History

    Over the 8 of the 10 year ends shown that have a P/S, its P/S ranged from 2.0x in 2016 to 526.4x in 2022.

    Year endPriceP/SP/B
    2025$31.1235.9x3.7x
    2024$19.17N/A2.3x
    2023$21.78N/A2.4x
    2022$29.21526.4x3.0x
    2021$19.7749.3x1.2x
    2020$16.4549.2x0.5x
    2019$7.203.4x1.0x
    2018$45.4310.1x1.8x
    2017$156.3751.5x6.0x
    2016$75.112.0xN/A
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported.

    Frequently Asked Questions About VRDN

    What is VRDN's forward P/E ratio?

    Viridian Therapeutics has a forward P/E ratio of 1.0x.

    What is VRDN's price to sales ratio?

    Viridian Therapeutics has a price to sales ratio of 128.5x.